WO2022202278A1

WO2022202278A1 - Pharmaceutical liquid administration device

Info

Publication number: WO2022202278A1
Application number: PCT/JP2022/009921
Authority: WO
Inventors: 城司内山; 剛山崎
Original assignee: テルモ株式会社
Priority date: 2021-03-25
Filing date: 2022-03-08
Publication date: 2022-09-29
Also published as: JPWO2022202278A1

Abstract

[Problem] To prevent leakage of a pharmaceutical liquid from a connection port caused by repetition of attachment and detachment between a device body and a cradle. [Solution] A pharmaceutical liquid administration device 100 is configured so that a connection port 40 is provided with a pharmaceutical liquid introduction part 421 having a communication hole 421c into which a pharmaceutical liquid fed from a liquid feed pipe 14 flows, and a housing 423 to which a liquid feed port 16 is attached and which is movably mounted on the pharmaceutical liquid introduction part 421, and the housing 423 is moved relative to the pharmaceutical liquid introduction part 421 in the direction D of attachment and detachment of a device body 101 to and from a cradle 30 to open the communication hole 421c, thereby allowing a fluid communication with the liquid feed port 16.

Description

Liquid dosing device

The present invention relates to a drug solution administration device that administers a drug solution to an object such as a living body.

A treatment method that continuously administers a drug solution into the patient's body is known. For example, as a therapeutic method for diabetic patients, a therapeutic method of continuously administering a small amount of insulin into the body is known. For this therapy, a portable medical-solution administration device that can be fixed to the user's body or clothes is used. If a portable liquid medicine administration device is used, the liquid medicine can be administered to the user all day long. An insulin pump that administers insulin to a user is known as this type of drug-solution administration device.

As one of the portable liquid medicine administration devices described above, there is a syringe pump type liquid medicine injection device having a syringe (reservoir) in which a liquid medicine is stored and a pusher (pump mechanism) driven inside the syringe. Proposed. In a syringe pump type drug solution administration device, a cannula is liquid-tightly connected to a liquid delivery tube extending from a syringe, and the cannula is inserted under the skin of a user to be retained, and a plunger is driven to store the liquid in the syringe. It is designed to inject the drug into the body of the user.

In Patent Document 1, a needle member (liquid feeding needle) having a needle tube for liquid feeding is provided at the tip of a liquid feeding tube, while a connection port having a cannula is provided with a rubber partition (rubber plug) to feed liquid. A technique for connecting a liquid delivery tube and a cannula by piercing a rubber plug with a needle is described.

WO2008/078318

However, the technology described in Patent Document 1 has the following problems. A drug-solution administration device such as an insulin pump includes a device main body and a cradle that are detachable from each other. The cradle is attached and fixed to the user's skin, and the device body is attached to and detached from the cradle. Further, the above-described reservoir, pump mechanism, liquid-sending tube and liquid-sending needle are provided in the apparatus main body, and the above-described connection port is provided in the cradle. Then, when the device main body is mounted on the cradle, the liquid feeding needle is configured to pierce the rubber plug.

However, during use of the medicinal solution administration device, for some reason, for example, when the user takes a bath or fills the reservoir with medicinal solution, it is necessary to remove the main body of the device from the cradle. Then, it is necessary to attach the device body to the cradle again. Therefore, during use of the drug solution administration device, the device body and the cradle are repeatedly attached and detached, and the rubber plug is punctured and removed by the number of repetitions. As a result, for example, the puncture hole of the rubber plug may be widened or the rubber plug itself may be damaged, so that the liquid medicine may leak from the connecting portion between the rubber plug and the liquid feeding needle.

At least one embodiment of the present invention has been made in view of the circumstances described above. It is an object of the present invention to provide a drug solution administration device capable of

A drug-solution administration device according to this embodiment includes a connection port for holding a cannula inserted into a living body, a cradle attached to the living body, a reservoir for storing a drug solution, and a drug solution from the reservoir. a device main body comprising a liquid-feeding drive unit for feeding, a liquid-feeding pipe through which the drug solution fed from the reservoir flows, and a hollow cylindrical liquid-feeding port communicating with the liquid-feeding pipe, A drug solution administration device in which the liquid delivery port and the connection port are detachably fluidly connected, wherein the connection port is a drug solution introduction part having a communication hole for inflowing the drug solution delivered from the liquid delivery pipe; a housing portion to which the liquid delivery port is attached and which is movable with respect to the chemical solution introduction portion, the housing portion being moved relative to the chemical solution introduction portion in a direction in which the apparatus body is attached to and detached from the cradle. By doing so, the communication hole is opened and configured to be fluidly connected to the liquid transfer port.

According to at least one embodiment of the present invention, it is possible to prevent leakage of the chemical solution from the connection port due to repeated attachment/detachment work between the apparatus main body and the cradle.

1 is a schematic perspective view of a drug-solution administration device according to a first embodiment; FIG. 1 is a schematic exploded perspective view of a drug-solution administration device according to a first embodiment; FIG. 1 is a schematic partial perspective view of a drug-solution administration device according to a first embodiment, viewed from the side; FIG. 3 is a schematic partial cross-sectional view of the vicinity of a connection port of the drug-solution administration device according to the first embodiment; FIG. 4 is a schematic cross-sectional view showing a sealed state of a connection port of the drug-solution administration device according to the first embodiment; FIG. 4 is a schematic cross-sectional view showing an opened state of a connection port of the drug-solution administration device according to the first embodiment; FIG. It is a schematic sectional drawing which shows the connection method of the medical-solution administration apparatus which concerns on 1st Embodiment. It is a schematic sectional drawing which shows the connection method of the medical-solution administration apparatus which concerns on 1st Embodiment. It is a schematic sectional drawing which shows the connection method of the medical-solution administration apparatus which concerns on 1st Embodiment. It is a schematic sectional drawing which shows the connection method of the medical-solution administration apparatus which concerns on 1st Embodiment. FIG. 11 is a schematic partial perspective view of a cradle of a medical-solution administration device according to a second embodiment; FIG. 11 is a schematic cross-sectional view showing a sealed state of a connection port of a drug-solution administration device according to a second embodiment; FIG. 11 is a schematic cross-sectional view showing an opened state of a connection port of a drug-solution administration device according to a second embodiment; FIG. 10 is a schematic cross-sectional view showing a method of connecting the drug-solution administration device according to the second embodiment; FIG. 10 is a schematic cross-sectional view showing a method of connecting the drug-solution administration device according to the second embodiment; FIG. 10 is a schematic cross-sectional view showing a method of connecting the drug-solution administration device according to the second embodiment; FIG. 10 is a schematic cross-sectional view showing a method of connecting the drug-solution administration device according to the second embodiment; FIG. 11 is a schematic cross-sectional view showing a sealed state of a connection port of a drug-solution administration device according to a third embodiment; FIG. 11 is a schematic cross-sectional view showing an opened state of a connection port of a drug-solution administration device according to a third embodiment; FIG. 11 is a schematic cross-sectional view showing a method of connecting a drug-solution administration device according to a third embodiment; FIG. 11 is a schematic cross-sectional view showing a method of connecting a drug-solution administration device according to a third embodiment; FIG. 11 is a schematic cross-sectional view showing a method of connecting a drug-solution administration device according to a third embodiment;

Hereinafter, embodiments for carrying out the present invention will be described in detail with reference to the drawings. The embodiment shown here is an example for embodying the technical idea of the present invention, and does not limit the present invention. In addition, other practicable modes, embodiments, operation techniques, etc. that can be conceived by those skilled in the art without departing from the gist of the present invention are all included in the scope and gist of the present invention, and are described in the scope of claims. included within the scope of the claimed invention and its equivalents.

Furthermore, the drawings attached to this specification may be represented schematically by appropriately changing the scale, length-to-width ratio, shape, etc. from the actual thing for the convenience of illustration and ease of understanding. and does not limit the interpretation of the present invention.

In addition, in the following explanation, when ordinal numbers such as "first" and "second" are used for explanation, unless otherwise specified, they are used for convenience and do not prescribe any order.

In this specification, for convenience of explanation, XYZ coordinates are set as shown. That is, the "Z direction" is a direction along the vertical direction, the "X direction" is a direction perpendicular to the Z direction and parallel to the horizontal plane, and the "Y direction" is perpendicular to the Z direction and parallel to the horizontal plane. is another direction (a direction perpendicular to the X direction). Therefore, in the drug-

solution administration devices

100, 110, and 120 according to this embodiment, the Z direction coincides with the thickness direction (vertical direction) of the device, and the X direction is the longitudinal direction (front-back direction) along the axial direction of the device. That is, the Y direction coincides with the lateral direction (width direction) perpendicular to the longitudinal direction of the device.

The drug

solution administration devices

100, 110, and 120 according to this embodiment are devices for continuously administering a drug solution into the user's body. The drug solutions administered using the drug

solution administration devices

100, 110, and 120 include, for example, insulin, analgesics, anticancer drugs, HIV (Human Immunodeficiency Virus) drugs, iron chelating drugs, and pulmonary hypertension drugs. In this embodiment, as an example of the drug-

solution administration devices

100, 110, and 120, a portable insulin pump that administers insulin into the user's body is assumed. Drug-

solution administration devices

100, 110, and 120, which are insulin pumps, are used by being attached to the surface of a living body. The biological surface is typically the surface of the user's skin. Also, the position where the drug-

solution administration devices

100, 110, and 120 are attached is, for example, the abdomen of the user.

[First embodiment]
FIG. 1 is a schematic perspective view showing the appearance of a medical-solution administration device 100 according to the first embodiment, and FIG.

<Configuration>
As shown in FIG. 1 or FIG. 2, the medicinal-solution administration device 100 generally includes a first body portion 10 holding a reservoir 12 in which a medicinal solution is stored, etc. and a cradle 30 that holds the cannula 50 and is attached to the surface of the living body.

The first main body part 10 is a disposable part. The second body portion 20 is a reuse portion. The first body portion 10 and the second body portion 20 are connected to each other so as to be separable. A device main body 101 of the drug-solution administration device 100 is configured in a state where the first main body portion 10 and the second main body portion 20 are connected. The device main body 101 is connected to the cradle 30 .

<First main unit>
The first body portion 10 has a housing 11 , a reservoir 12 , an extrusion portion 13 , a liquid feeding tube 14 and a power supply portion 15 . The housing 11 is formed in a substantially rectangular shape when viewed from above (as viewed in the Z direction). Further, the housing 11 is a substantially rectangular parallelepiped with an upper opening.

As shown in FIG. 2, the housing 11 includes a flat bottom surface portion 11a and a side wall portion 11b that rises along the entire outer periphery of the bottom surface portion 11a. The bottom surface portion 11a is a plate portion that partitions the housing 11 in the Z direction. The bottom surface portion 11a is arranged to face the cradle 30 when the first main body portion 10 is attached to the cradle 30. As shown in FIG. A reservoir 12, an extruding portion 13, a liquid feeding pipe 14, and a power source portion 15 are attached to the surface of the bottom surface portion 11a facing the second main body portion 20 (upper surface of the bottom surface portion 11a). The bottom surface portion 11a also functions as a bottom surface portion of the device main body 101 in which the second main body portion 20 is attached to the first main body portion 10 .

The housing 11 includes a first storage portion 11c surrounded by a bottom portion 11a and a side wall portion 11b. The first storage portion 11c is a space provided on the upper surface side of the bottom surface portion 11a, and stores the reservoir 12, the power source portion 15, and the like. Further, when the lid 21 of the second main body 20 and the housing 11 are connected, the liquid feeding driving section 23 attached inside the lid 21 is accommodated in the first storage section 11c.

The housing 11 includes a second storage section 11d (see FIG. 3). The second storage portion 11d is a space recessed in the thickness direction (Z direction) of the housing 11 with respect to the lower surface of the bottom surface portion 11a (the surface on the side connected to the cradle 30). The connection port 40 of the cradle 30 and the like are accommodated in the second accommodation portion 11d. The first storage portion 11c and the second storage portion 11d are separated by a partition wall 11e.

The reservoir 12 has an outer cylinder 12a in which the liquid medicine to be administered to the user is stored, and the liquid medicine in the outer cylinder 12a is discharged by the pushing action of the pushing part 13. The reservoir 12 is provided with a liquid discharge port (not shown) at its tip, and one end of a liquid transfer pipe 14 is connected to this discharge port. The other end of the liquid-sending pipe 14 is connected to the liquid-sending port 16 from the first housing portion 11c side of the housing 11 . A gear 12b is provided near the end of the reservoir 12 . The gear 12b rotates by receiving the driving force of the liquid feeding driving section 23. As shown in FIG. A feed screw 12c meshes with the end of the rotating shaft of the gear 12b. The feed screw 12c is provided movably in the X direction. In the reservoir 12, the gear 23b and the gear 12b are rotated by the drive of the liquid feeding driving section 23, and the feed screw 12c rotates according to the rotation of the gear 12b, thereby moving the extruding section 13 in the X direction. The drug solution in the reservoir 12 is delivered to the liquid delivery pipe 14 according to the pushing amount of the pushing portion 13 that moves as the feed screw 12c rotates. The liquid-sending pipe 14 is detachably fluidly connected to a connection port 40 to be described later via the liquid-sending port 16 (connected state in which the chemical liquid can flow).

It should be noted that the reservoir 12 is not limited to a syringe, and may be any device capable of storing a liquid medicine, such as a soft bag. The reservoir 12 only needs to be able to discharge the chemical liquid by the pushing portion 13 .

The power supply unit 15 supplies drive power necessary for driving the drug-solution administration device 100 . The power source unit 15 is composed of, for example, a battery that serves as a power source for driving the liquid feeding driving unit 23 and a battery box that houses the battery. The power supply unit 15 is connected to electrodes (not shown) on the circuit board 22 . Note that the power supply unit 15 may be arranged inside the lid 21 as a component of the second main body 20 .

As shown in FIG. 3, the liquid transfer port 16 is provided so as to protrude from the second storage portion 11d. The liquid-sending port 16 has a hollow cylindrical shape with a liquid-sending hole 16a formed at its tip. The liquid-sending port 16 is connected to the liquid-sending tube 14 at its proximal end and attached to a connection port 40 provided at the cradle 30 at its distal end. The liquid feeding hole 16 a is formed to pass through the liquid feeding port 16 along the central axis of the liquid feeding port 16 . The opening end face of the liquid feeding hole 16a may have, for example, radial (in other words, cross-shaped) grooves around the liquid feeding hole 16a.

<Second main body>
The second body portion 20 has a lid body 21 , a circuit board 22 , and a liquid feeding driving portion 23 , and is attached to the first body portion 10 . The second body portion 20 is a portion where the electronic control functions of the drug-solution administration device 100 are collectively arranged. The second body portion 20 is configured by accommodating electronically controlled functional components such as a circuit board 22 and a liquid feeding driving portion 23 inside a lid body 21 .

The lid 21 is configured to be detachable from the housing 11 of the first main body 10 . The upper surface of the lid body 21 forms the top surface of the medical-solution administration device 100 . Electronically controlled functional components such as the circuit board 22 and the liquid transfer driving unit 23 are attached to the lower surface side of the lid 21 .

The liquid feeding drive unit 23 includes a motor 23a and a gear 23b. The motor 23a is a driving source for moving the pushing portion 13 in a predetermined direction to deliver the liquid medicine in the reservoir 12. As shown in FIG. The gear 23b is composed of a plurality of stages of gears, and the gear of the final stage meshes with the gear 12b. As a result, the driving force (rotational force) of the motor 23a is transmitted to the gear 12b via the gear 23b.

In addition, the second main unit 20 includes a liquid feeding amount detection unit 24 such as an encoder capable of detecting the liquid feeding amount based on the number of revolutions of a motor 23a, and an interface for enabling communication with the outside. and a control unit 26 configured by a known microcomputer including a CPU, ROM, RAM, and the like. The communication unit 25 and the liquid transfer driving unit 23 operate according to a predetermined program under the control of the control unit 26 .

<Cradle>
The cradle 30 has a holder case 31 and a connection port 40 . The holder case 31 includes a mounting surface portion 31a and side wall portions 31b. The connection port 40 is attached to the upper surface (mounting surface portion 31a) of the holder case 31 . The apparatus main body 101 is attached to and detached from the cradle 30 by sliding in the attachment/detachment direction D (attachment direction D1 or detachment direction D2) along the X direction.

The holder case 31 is provided with an adhesive portion 31c on its lower surface. The adhesive portion 31c is a portion that protrudes greatly outward from the placement surface portion 31a, and is a portion for attaching the cradle 30 to the living body surface (user's skin). The mounting surface portion 31a is formed in a substantially rectangular shape in plan view.

When the first body portion 10 is mounted on the cradle 30, the bottom surface portion 101a of the apparatus body 101 (bottom portion 11a of the first body portion 10) is placed on the loading surface portion 31a. The side wall portions 31b are formed to stand in the thickness direction (Z direction) of the cradle 30 from three sides of the mounting surface portion 31a, and the side wall portion 31b is not formed on the remaining one side of the mounting surface portion 31a. As a result, the device main body 101 can be attached/detached to/from the cradle 30 by sliding in the attachment/detachment direction D from the portion where the side wall portion 31b is not formed. The attachment/detachment direction D is a direction along the surface of the mounting surface portion 31a.

A rib 31d that guides the connection between the first body portion 10 and the cradle 30 is provided on the upper surface of the mounting surface portion 31a of the holder case 31. The rib 31d extends in the longitudinal direction of the cradle 30 along the X direction at substantially the central portion of the placement surface portion 31a in the width direction (Y direction). The first body portion 10 is mounted parallel to the surface of the cradle 30 so as to be slid. The rib 31d engages with a recessed groove (not shown) provided on the lower surface of the bottom surface 11a of the first main body 10, and guides the sliding movement of the apparatus main body 101. As shown in FIG.

<Connection port>
The connection port 40 is provided on the upper surface of the mounting surface portion 31a of the cradle 30, as shown in FIG. 4 or FIG. The connection port 40 includes a first connection portion 42 and a second connection portion 43 in a port body 41 . The connection port 40 is a port connected to the liquid transfer pipe 14 via the first connection portion 42 .

The first connecting part 42 is arranged on the side wall of the port body 41 facing the liquid feeding port 16, and introduces into the connecting port 40 the liquid medicine delivered through the liquid feeding port 16 when the device body 101 is attached to the cradle 30. Acts as an introduction port to The second connection part 43 is arranged above the connection port 40 and functions as a puncture port through which a known puncture tool (not shown) is punctured when the cannula 50 is left in the living body.

A holding portion 44 that holds a cannula 50 that is indwelled in the living body and feeds the drug solution into the living body is provided at the lower portion of the port body 41 of the connection port 40 . The cannula 50 protrudes from the holding portion 44 toward the user's body, and at least the tip portion is left in the living body. The cannula 50 is made of a resin material such as polyurethane, nylon, ethylene-tetrafluoroethylene copolymer (ETFE). After inserting the cannula 50 into the living body, the puncture tool is removed from the cradle 30 and discarded.

The holding part 44 is formed in a funnel shape to guide the inflowing drug solution to the cannula 50 and hold the cannula 50 in the port body 41 . A predetermined internal space 45 is provided above the holding portion 44 and communicates with the first connection portion 42 and the second connection portion 43 .

The first connection portion 42 includes a chemical liquid introduction portion 421 , a first seal portion 422 , a housing portion 423 , a lever portion 424 and a second seal portion 425 .

The drug solution introduction part 421 is a hollow member that extends outward from the side wall of the port body 41 in a substantially horizontal direction and has a communication hole 421c. The chemical introduction part 421 extends in the attachment/detachment direction D from the port main body 41 . The communicating passage 421a of the liquid medicine introducing portion 421 communicates with the internal space 45 and also communicates with the liquid feeding hole 16a of the liquid feeding port 16 connected to the first connecting portion 42 via the later-described communicating hole 421c. As a result, the chemical liquid delivered from the liquid delivery port 16 is introduced into the connection port 40 . A plurality of communication holes 421c are provided in a distal end surface 421b of the chemical liquid introducing portion 421. As shown in FIG.

The communication hole 421c may be closed when the tip surface 421b of the liquid medicine introduction portion 421 and the inner surface 423b of the housing portion 423 are in contact with each other, as shown in FIG. 5A. More specifically, the communication hole 421c operates the lever portion 424 in a predetermined operation direction (mounting direction D1), and moves the housing portion 423 so that the inner surface 423b of the housing portion 423 abuts the distal end surface 421b of the liquid introducing portion 421. It may be closed when moved to the closed position. By closing the communication hole 421 c , the internal space 45 can block communication with the outside when the device main body 101 is not attached to the cradle 30 . In addition to the sealing portion provided between the projection portion 421d and the second sealing portion 425, which will be described later, the inner surface 423b of the housing portion 423 and the tip surface 421b of the chemical liquid introduction portion 421 can also be closed. It is possible to improve the sealing performance.

As shown in FIG. 5B, the communication hole 421c is opened in a state in which the tip surface 421b of the liquid medicine introduction portion 421 and the inner surface 423b of the housing portion 423 are not in contact with each other. Specifically, the lever portion 424 is operated in a predetermined operation direction (withdrawal direction D2) to move the housing portion 423 to the open position so that the inner surface 423b of the housing portion 423 is separated from the distal end surface 421b of the liquid introducing portion 421. When it is closed, the communication hole 421c is opened. By opening the communication hole 421c, the internal space 45 communicates with the liquid transfer port 16 when the device main body 101 is attached to the cradle 30, forming a chemical liquid flow path. That is, the liquid-sending port 16 (liquid-sending pipe 14) and the connection port 40 are fluidly connected so that the chemical liquid can flow.

A protruding portion 421d that protrudes outward with respect to the tip surface 421b is provided at a substantially central portion of the tip surface 421b of the liquid medicine introduction portion 421. When the housing portion 423 is in the closed position, the projection portion 421d is fitted and mounted on the mounting portion 423a of the housing portion 423, and the outer peripheral surface of the projection portion 421d is in close contact with the second seal portion 425. As shown in FIG. As a result, the internal space 45 is cut off from communication with the outside and is liquid-tightly sealed.

The above-mentioned "closed position" is the position of the housing portion 423 in a state where the communicating passage 421a of the chemical solution introduction portion 421 is closed and the fluid connection between the liquid supply port 16 and the connection port 40 is cut off. Further, the “open position” is the position of the housing portion 423 in a state in which the communicating passage 421a of the chemical liquid introduction portion 421 is opened and the liquid feeding port 16 and the connection port 40 are fluidly connected.

The first seal portion 422 is housed in an annular first housing recess 421e provided on the outer circumference of the chemical introduction portion 421. Since the outer peripheral surface of the first seal portion 422 and the inner peripheral surface of the housing portion 423 are brought into close contact with each other by the first seal portion 422, the liquid medicine is prevented from leaking to the outside through the gap between the liquid medicine introduction portion 421 and the housing portion 423. In addition, it is possible to improve the liquid tightness in the connection state between the liquid feeding port 16 and the chemical liquid introducing portion 421 . The first sealing portion 422 can be an O-ring made of a flexible and sealing material such as a rubber material, silicone elastomer, or thermoplastic elastomer.

The housing part 423 is attached so as to be slidable along the axial direction (attachment/detachment direction D) of the chemical solution introducing part 421 so as to cover the tip portion of the chemical solution introducing part 421 . A mounting portion 423a having a hollow tubular shape protrudes from a substantially central portion of the housing portion 423. As shown in FIG. An annular second storage recess 423c is provided on the inner peripheral surface of the mounting portion 423a, and the second seal portion 425 is stored therein. When the device main body 101 is mounted on the cradle 30, the liquid feeding port 16 is inserted into the mounting portion 423a. Thereby, the device main body 101 and the cradle 30 are connected.

The lever part 424 slides the housing part 423 between the closed position and the open position with the medicinal-solution administration device 100 attached to the living body. One end of the lever portion 424 is connected to the outer periphery of the housing portion 423, and the other end is exposed to the outside of the holder case 31 of the cradle 30 and used as a grip portion 424a. The lever portion 424 extends from the housing portion 423 through the opening 31e of the holder case 31 to the outside of the holder case 31 from the side wall portion 31b via a notch (not shown) provided on the lower surface of the holder case 31. (see Figure 6).

The second seal portion 425 is housed in a second housing recess 423c provided on the inner peripheral surface of the mounting portion 423a. The second seal portion 425 is in close contact with the outer peripheral surface of the liquid transfer port 16 when the housing portion 423 is in the open position with the device main body 101 and the cradle 30 attached. Thereby, the second sealing portion 425 can improve the liquid tightness in the connection state between the liquid feeding port 16 and the chemical liquid introducing portion 421 . Further, as described above, the second seal portion 425 is in close contact with the outer peripheral surface of the projection portion 421d when the housing portion 423 is in the closed position, and blocks communication of the internal space 45 with the outside. The second sealing portion 425 can be an O-ring made of a flexible and sealing material such as a rubber material, silicone elastomer, or thermoplastic elastomer.

The second connecting portion 43 includes an opening 431 and a plug 432, and when the cannula 50 is left in the living body, the puncture needle is punctured through the opening 431 together with the cannula 50, and then only the puncture needle is removed. be done. The opening hole 431 is provided on the upper surface of the port body 41 . A stopper 432 is arranged directly below the opening hole 431 .

The stopper 432 is arranged above the holding portion 44 and at a position facing the proximal end of the cannula 50 . The plug 432 is flexible and has a self-sealing function, for example, various rubber materials such as silicone rubber and natural rubber, and various thermoplastic elastomers such as polyurethane, polyester, polyamide, olefin, and styrene. can be constructed of a material having The plug 432 closes the internal space 45 by sealing the second connecting portion 43 after the puncture needle that has passed through the plug 432 is removed.

<Action>
Next, in the medicinal-solution administration device 100 according to the first embodiment, see FIGS. 6 to 9 for the operation when the device main body 101 is attached to the cradle 30 and the operation when the device main body 101 is removed from the cradle 30. I will explain while

As a preliminary step to using the medical-solution administration device 100, the user attaches the cradle 30 to the surface of the living body and places the cannula 50 inside the living body with a puncture tool. When indwelling the cannula 50, the user adheres the adhesive portion 31c of the cradle 30 to the skin and then pierces the second connecting portion 43 with the puncture needle to insert the cannula 50 into the living body. As a result, the cradle 30 is attached to the surface of the living body while the cannula 50 remains in the living body. As shown in FIG. 6, before the device main body 101 is attached to the cradle 30, the housing portion 423 of the connection port 40 is positioned at the closed position, and the internal space 45 is kept sealed.

Next, the user attaches the second main body portion 20 to the first main body portion 10 to assemble the device main body 101 .

Next, as shown in FIG. 7, the user slides the assembled apparatus main body 101 with respect to the cradle 30 in the mounting direction D1 along the X direction (leftward in the drawing) to mount the apparatus main body 101 thereon. At this time, the lower surface of the bottom surface portion 11a of the housing 11 is placed on one end of the mounting surface portion 31a of the cradle 30, and the apparatus main body 101 is placed while the ribs 31d are engaged with the grooves of the bottom surface portion 11a. It is slid parallel to the placement surface portion 31a. Thereby, the apparatus main body 101 is placed on the cradle 30 . Further, by this sliding operation, the liquid feeding port 16 is fitted and connected to the mounting portion 423a of the first connecting portion 42 . As shown in FIG. 7, even when the device main body 101 is attached to the cradle 30, the connection port 40 keeps the internal space 45 sealed because the housing portion 423 is positioned at the closed position.

Subsequently, the user operates the lever portion 424 to move the housing portion 423 from the closed position to the open position. As shown in FIG. 8, when the lever portion 424 is operated to move the housing portion 423 from the closed position to the open position, the projection portion 421d fitted to the mounting portion 423a of the housing portion 423 is released. , are released as the housing portion 423 is moved to the open position. As a result, the contact state between the outer surface of the protrusion 421d and the second seal portion 425 is released. 8, the communication hole 421c is opened when the inner surface 423b of the housing portion 423 is separated from the tip end surface 421b of the chemical liquid introducing portion 421. As shown in FIG. As a result, the connection port 40 is brought into an open state, and a liquid medicine flow path is formed in which the internal space 45 and the liquid feeding port 16 communicate with each other, so that the liquid medicine administration device 100 can administer the liquid medicine.

The drug solution channel is a channel that connects to the cannula 50 within the connection port 40 . Therefore, fluid connection is established between the liquid feeding tube 14 connected to the reservoir 12 and the cannula 50 to be punctured into the living body. Therefore, when the user activates the medical-solution administration device 100 , the liquid-feeding driving unit 23 is driven at a predetermined timing, and the medical liquid stored in the reservoir 12 is delivered from the liquid-feeding port 16 via the liquid-feeding pipe 14 . It can flow into the introduction part 421 . Then, the drug solution that has flowed into the drug solution introduction part 421 flows through the internal space 45 of the port body 41 into the cannula 50 and is introduced into the living body.

When removing the device body 101 from the cradle 30 during use of the drug-solution administration device 100, as shown in FIG. The main body 101 is slid. As a result, the apparatus main body 101 is separated from the cradle 30, the liquid transfer port 16 is removed from the mounting portion 423a of the first connection portion 42, and the connected state is released. Then, the user operates the lever portion 424 to move the housing portion 423 from the open position to the closed position. When the housing portion 423 moves to the closed position, the projection portion 421d is fitted with the mounting portion 423a of the housing portion 423, and the outer peripheral surface of the projection portion 421d and the second seal portion 425 are in close contact. Further, as shown in FIG. 9, the communication hole 421c is closed when the inner surface 423b of the housing portion 423 and the tip end surface 421b of the liquid medicine introducing portion 421 come into contact with each other. As a result, the connection port 40 is sealed and the internal space 45 is separated from the outside.

[Second embodiment]
Next, a drug-solution administration device 110 according to a second embodiment will be described with reference to FIGS. 10 to 16. FIG. In the second embodiment, constituent elements having the same functions as those of the first embodiment described above are denoted by the same reference numerals, and detailed descriptions thereof are omitted. , may be similar to the previously described embodiment.

A second embodiment described below shows a configuration in which the movement form of the housing portion 423 is changed.

<Configuration>
In the drug-solution administration device 110 according to the second embodiment, when the device main body 111 with the second main body portion 20 attached to the first main body portion 10 is detached from the cradle 30 , the housing portion 423 slides the device main body 111 . Along with this, it moves from the open position to the closed position. In order to realize such an operation, in the medicinal-solution administration device 110 according to the second embodiment, the forms of the lever portion 424 connected to the housing portion 423 and the holder case 31 of the cradle 30 are changed.

Specifically, as shown in FIG. 10, the lever portion 424 has one end connected to the outer periphery of the housing portion 423 and the other end connecting the bottom portion 11a (bottom portion 111a) side of the holder case 31 of the cradle 30 to the housing portion 423 . It becomes the tip of the extending portion 424b extending from the end portion 424b by a predetermined length in the detaching direction D2. The extending portion 424b is housed in a notch portion (not shown) provided in the holder case 31 so as to be movable in the attachment/detachment direction D. As shown in FIG. The lever portion 424 includes an engaging claw 424c that engages with an engaging recess 11f provided on the lower surface of the bottom surface portion 11a of the first main body portion 10 near the tip of the extending portion 424b. The engaging recess 11f and the engaging claw 424c engage through the opening 31e of the holder case 31 when the device main body 111 is attached to the cradle 30 . As an example, the engaging claw 424c is a projection projecting upward in the Z direction from the surface of the extension 424b. The thickness of the engaging claw 424c gradually decreases in the detachment direction D2.

The engaging claw 424c partially protrudes from the opening 31e before the device main body 111 is attached to the cradle 30 (see FIG. 12). When the device main body 111 is slidably mounted on the cradle 30 along the mounting direction D1, the engaging claw 424c is temporarily moved downward from the surface of the holder case 31 by the bottom surface portion 11a of the first main body portion 10. Save (see FIG. 13). After that, when the apparatus main body 111 is attached to the cradle 30, the engaging claw 424c moves toward the opening 31e again at the timing when the engaging recess 11f moves to the position of the opening 31e, and engages with the engaging recess 11f. (see Figure 14).

Further, when the device main body 111 slides from the cradle 30 in the detachment direction D2, the engaging claw 424c remains engaged with the engaging recess 11f until the engagement between the two is released. Move in direction D2. As a result, the housing portion 423 coupled with the lever portion 424 moves from the open position to the closed position. The engagement state between the engaging claw 424c and the engaging recess 11f is maintained only while the apparatus main body 101 is moved from the cradle 30 in the detaching direction D2 by a predetermined distance until the engaging recess 11f is moved out of the opening 31e. and then released.

The configuration of the connection port 40 according to the second embodiment is partially changed in accordance with the change in the configuration of the lever portion 424 . As shown in FIG. 11A or FIG. 11B, the connection port 40 according to the second embodiment has a third housing portion 423d for housing the first seal portion 422 provided in the lumen of the mounting portion 423a, and a communication hole 421c as a protrusion. It is provided on the peripheral surface of 421d. In addition, the projecting portion 421d has a restricting portion 421f that restricts movement of the housing portion 423. As shown in FIG. The restricting portion 421f is arranged on the base end side of the protruding portion 421d at a position separated from the distal end surface of the liquid medicine introducing portion 421 . The restricting portion 421f abuts against the inner surface 423b of the housing portion 423 to restrict movement of the housing portion 423 toward the connection port 40 side.

The communication hole 421c is provided on the outer peripheral surface of the protruding portion 421d facing the inner surface 423b of the housing portion 423 (the outer peripheral surface of the chemical liquid introduction portion 421), penetrating inwardly through the outer peripheral surface of the protruding portion 421d. As in the second embodiment or a third embodiment described later, a space serving as a chemical liquid flow path may be provided inside the protrusion 421d. As shown in FIG. 11A, when the housing portion 423 is positioned at the closed position, the communication hole 421c comes into close contact with the first seal portion 422 as the housing portion 423 moves in the attachment/detachment direction D. As a result, the connection port 40 is liquid-tightly sealed, and the internal space 45 is kept sealed. When the housing portion 423 is positioned at the open position, the communication hole 421c is released from the close contact with the first seal portion 422 as shown in FIG. 11B. As a result, the connection port 40 is opened, and the liquid transfer port 16 and the internal space 45 are communicated with each other to form a chemical liquid flow path.

The liquid feed port 16 according to the second embodiment is for moving the housing portion 423 from the closed position to the open position by sliding the device main body 111 in the mounting direction D1 when the device main body 111 is mounted on the cradle 30. A contact portion 16b is provided. The abutting portion 16b is provided on the outer circumference of the liquid feeding port 16, and when the device main body 111 is mounted on the cradle 30, the sliding movement of the device main body 111 in the mounting direction D1 causes the tip end surface of the mounting portion 423a of the housing portion 423 to move. The housing portion 423 is pushed in from the closed position to the open position while being in contact with the .

<Action>
Next, referring to FIGS. 12 to 15 for the operation of attaching the device body 111 to the cradle 30 and the operation of removing the device body 111 from the cradle 30 in the medical-solution administration device 110 according to the second embodiment. I will explain while

As a preliminary step to using the drug-solution administration device 100, the user attaches the cradle 30 to the surface of the living body and places the cannula 50 in the living body, as in the first embodiment. Next, the user attaches the second body portion 20 to the first body portion 10 to assemble the device body 111 . As shown in FIG. 12, before the device main body 111 is attached to the cradle 30, the housing portion 423 of the connection port 40 is positioned at the closed position, so that the communication hole 421c and the first seal portion 422 are in close contact with each other. there is Therefore, the internal space 45 is in a sealed state, and the sealed state is maintained.

Next, as shown in FIG. 13, the user slides the assembled apparatus main body 111 onto the cradle 30 in the mounting direction D1 (to the left in the drawing) along the X direction to temporarily mount the apparatus main body 111. . At this time, the lower surface of the bottom surface portion 11a of the housing 11 is placed on one end of the mounting surface portion 31a of the cradle 30, and the main body 111 is placed while the ribs 31d are engaged with the grooves of the bottom surface portion 11a. It is slid parallel to the placement surface portion 31a. As a result, the device body 111 is placed on the cradle 30 . 13, the engaging claw 424c of the lever portion 424 abuts against the lower surface of the holder case 31, so that it is temporarily retracted downward from the mounting surface portion 31a of the holder case 31. As shown in FIG. As shown in FIG. 13, when the apparatus main body 111 is not completely attached to the cradle 30, the housing portion 423 of the connection port 40 is still in the closed position, and the internal space 45 is not sealed. retained. Also, the tip of the liquid transfer port 16 is fitted into the mounting portion 423 a and closely attached to the second seal portion 425 .

Subsequently, the user further slides the device main body 111 to completely attach the device main body 111 to the cradle 30 as shown in FIG. By this sliding operation, the liquid feeding port 16 is fitted and connected to the mounting portion 423a of the first connecting portion 42 . In addition, when the device main body 111 is attached to the cradle 30, the engaging recess 11f of the first main body 10 moves to a position facing the opening 31e. Therefore, the engaging claw 424c of the lever portion 424 can engage with the engaging recess 11f through the opening 31e.

Further, when the device main body 111 is attached to the cradle 30, the housing portion 423 is pushed by the contact portion 16b of the liquid feeding port 16 and moves from the closed position to the open position. As a result, the communicating hole 421c is released from the close contact with the first seal portion 422 . Therefore, the connection port 40 is in an open state, a liquid medicine flow path is formed in which the internal space 45 and the liquid feeding port 16 are in communication, and the liquid medicine administration device 110 can administer the liquid medicine.

When removing the device main body 111 from the cradle 30 during use of the drug-solution administration device 110, as shown in FIG. The main body 111 is slid. The engaging claw 424c is engaged with the engaging recess 11f. Therefore, the lever portion 424 moves in the detachment direction D2 as the device main body 111 is moved in the detachment direction D2. The lever portion 424 moves only until the apparatus main body 111 is slid and the engagement with the engaging recess 11f is released. Accordingly, housing portion 423 coupled with lever portion 424 moves from the open position to the closed position. As the housing portion 423 moves to the closed position, the communication hole 421c is brought into close contact with the first seal portion 422 . As a result, the connection port 40 is in a sealed state, the internal space 45 is sealed, and communication with the outside is cut off. In this manner, the flow path is opened and closed by moving the housing portion 423 relative to the chemical liquid introduction portion 421 in conjunction with the operation of attaching and detaching the device main body 111 to and from the cradle 30 .

[Third embodiment]
Next, a drug-solution administration device 120 according to a third embodiment will be described with reference to FIGS. 16 to 19. FIG. In the third embodiment, constituent elements having the same functions as those of the first and second embodiments described above are denoted by the same reference numerals, and detailed description thereof is omitted. The method of use and the like may be the same as in the above-described embodiment.

A third embodiment described below shows a configuration in which the movement form of the housing portion 423 is changed.

<Configuration>
In the drug solution administration device 120 according to the third embodiment, the drug solution introduction part 421 has a biasing member 421g arranged on the outer periphery of the protruding part 421d on the proximal side, and the housing part 423 is moved from the open position by the biasing force of the biasing member 421g. Move to closed position. In order to realize such an operation, in the drug solution administration device 120 according to the third embodiment, the lever part 424 connected to the housing part 423 is eliminated, and instead the biasing member 421g is arranged in the drug solution introduction part 421 to The portion 423 is always biased toward the closed position.

Specifically, as shown in FIG. 16A or 16B, the connection port 40 according to the third embodiment accommodates the first seal portion 422 in the third accommodation portion 423d, and has at least one communication hole 421c in the projection portion 421d. It is provided on the outer peripheral surface of Further, the projecting portion 421d is provided with a restricting portion 421f that restricts movement of the housing portion 423. As shown in FIG. The restricting portion 421f is provided on the base end side of the protruding portion 421d at a position separated from the distal end surface 421b of the liquid medicine introducing portion 421 . The restricting portion 421f abuts against the inner surface 423b of the housing portion 423 via the biasing member 421g to restrict movement of the housing portion 423 toward the connection port 40 side.

The biasing member 421g is arranged between the restricting portion 421f of the projecting portion 421d and the communicating hole 421c. For example, an elastic member such as a coil spring can be applied to the biasing member 421g. The biasing member 421g contacts the inner surface 423b of the housing portion 423 and biases the housing portion 423 to the closed position.

As shown in FIG. 16A, the housing part 423 is positioned at the closed position before the device main body 121 with the second main body part 20 attached to the first main body part 10 is attached to the cradle 30 . The communication hole 421c is provided so as to penetrate inwardly through the outer peripheral surface of the chemical liquid introducing portion 421 facing the inner surface 423b (the third storage portion 423d) of the housing portion 423 . When the housing portion 423 is positioned at the closed position, the communication hole 421c comes into close contact with the first seal portion 422 as the housing portion 423 moves in the attachment/detachment direction D and becomes closed. As a result, the internal space 45 is sealed, and the sealed state is maintained.

Further, as shown in FIG. 16B, the housing part 423 is interlocked with the sliding movement of the device main body 121 in the mounting direction D1 (left direction in the drawing) in a state where the device main body 121 is mounted on the cradle 30. It moves to the open position against the biasing force of the biasing member 421g. As a result, the communication hole 421c is released from the close contact with the first seal portion 422, and the liquid transfer port 16 and the internal space 45 are communicated with each other to form a chemical liquid flow path.

The liquid feed port 16 according to the third embodiment has a contact portion 16b for moving the housing portion 423 from the closed position to the open position when the apparatus main body 121 is attached to the cradle 30. The contact portion 16b is provided on the outer circumference of the liquid feeding port 16, and the size of the cross section in the Z direction of the contact portion 16b is larger than the size of the cross section of the opening of the mounting portion 423a. Therefore, when the device main body 121 is attached to the cradle 30, the contact portion 16b is kept in contact with the front end surface of the attachment portion 423a of the housing portion 423 due to the sliding movement of the device main body 121 in the attachment direction D1. 423 is pushed in and moved from the closed position to the open position.

<Action>
Next, referring to FIGS. 17 to 19 for the operation of attaching the device body 121 to the cradle 30 and the operation of removing the device body 121 from the cradle 30 in the medical-solution administration device 120 according to the third embodiment. I will explain while

As a pre-stage for using the drug-solution administration device 120, the user attaches the cradle 30 to the surface of the living body and places the cannula 50 in the living body, as in the first and second embodiments. Next, the user attaches the second body portion 20 to the first body portion 10 to assemble the device body 121 . As shown in FIG. 17, before the device main body 121 is attached to the cradle 30, the housing portion 423 of the connection port 40 is positioned at the closed position. there is Therefore, the internal space 45 is in a sealed state, and the sealed state is maintained.

Next, as shown in FIG. 18, the user slides the assembled device main body 121 with respect to the cradle 30 in the mounting direction D1 (leftward in the drawing) along the X direction to mount the device main body 121 thereon. At this time, the housing portion 423 is pushed by the contact portion 16b of the liquid feeding port 16 and moves from the closed position to the open position. As a result, the communicating hole 421c is released from the close contact with the first seal portion 422 . Therefore, the connection port 40 is in an open state, and a liquid medicine flow path is formed in which the internal space 45 and the liquid feeding port 16 communicate with each other, so that the liquid medicine administration device 120 can administer the liquid medicine.

When removing the device body 121 from the cradle 30 during use of the drug solution administration device 120, the user slides the device body 121 in the detachment direction D2 (to the right in FIG. 19), which is the opposite direction to the mounting direction. At this time, the housing portion 423 moves from the open position to the closed position due to the biasing force of the biasing member 421g. Further, as the housing portion 423 moves, the communication hole 421 c is brought into close contact with the first seal portion 422 . As a result, the connection port 40 is in a sealed state, the internal space 45 is sealed, and communication with the outside is cut off. In this manner, in conjunction with the operation of attaching and detaching the device main body 121 to and from the cradle 30 , the housing portion 423 moves relative to the liquid medicine introduction portion 421 to open and close the flow path.

[Effect]
As described above, the drug-

solution administration devices

100, 110 and 120 according to the present embodiment are equipped with the connection port 40 for holding the cannula 50 to be inserted into the living body, the cradle 30 attached to the living body, A reservoir 12 for storing a chemical solution, a liquid-sending drive unit 23 for sending the chemical solution from the reservoir 12, a liquid-sending pipe 14 through which the chemical solution sent from the reservoir 12 flows, and a liquid-sending port 16 communicating with the liquid-sending pipe 14. , and the liquid feeding port 16 and the connection port 40 are detachably fluidly connected. The connection port 40 includes a chemical solution introducing portion 421 having a communication hole 421c for inflowing the chemical solution sent from the solution sending tube 14, and a housing portion 423 to which the solution sending port 16 is attached and which is movably attached to the chemical solution introducing portion 421. By sliding the housing part 423 relative to the chemical solution introduction part 421 in the direction D in which the device

main bodies

101, 111, and 121 are attached to and detached from the cradle 30, the communication hole 421c is opened and the liquid transfer port is opened. configured to be in fluid connection with 16.

With the conventional technology, it was possible to repeatedly connect and close the flow path by piercing and removing a liquid feed needle with a sharp cutting edge from the self-sealing rubber plug (septum) provided in the connection port. As a result, in the prior art, as the number of attachments and detachments between the device main body and the cradle increases, for example, the piercing hole of the rubber plug widens or the rubber plug itself is damaged, and the connection between the rubber plug and the liquid feeding needle is damaged. There was a possibility that the chemical solution would leak out. On the other hand, the medical-

solution administration devices

100, 110 and 120 according to the present embodiment are configured to deliver the medical solution to the connection port 40 via the liquid-sending port 16 of the device

main bodies

101, 111, 121. 16 and the mounting portion 423 a of the housing portion 423 are mounted to fluidly connect the liquid feeding port 16 and the connection port 40 . As a result, the liquid

medicine administration devices

100, 110 and 120 according to the present embodiment prevent the liquid medicine from leaking from the connection port due to damage and deterioration of the rubber plug, which has been a problem in the prior art. In addition, the medical-

solution administration devices

100, 110, and 120 change the state of fluid connection between the liquid-feeding port 16 and the mounting portion 423a by moving the housing portion 423 relative to the medical-solution introduction portion 421 in the attaching/detaching direction D. can be controlled. As a result, the drug-

solution administration devices

100, 110, and 120 appropriately control the fluid connection between the liquid-feeding port 16 and the connection port 40 depending on whether the

device bodies

101, 111, and 121 and the cradle 30 are attached or not. be able to.

In addition, in the drug-

solution administration devices

100, 110 and 120 according to the present embodiment, the communication hole 421c is provided in the drug-solution introduction portion 421 facing the inner surface 423b of the housing portion 423, and the communication hole 421c extends in the attachment/detachment direction of the housing portion 423. With the movement to D, the outer peripheral surface of the drug solution introduction part 421 is sealed by the first seal part 422 and the second seal part 425 accommodated inside the housing part 423, whereby the drug

solution administration devices

100, 110 and 120 are sealed. The flow path may be configured to be opened and closed.

According to the drug-

solution administration devices

100, 110 and 120 configured in this way, the user can put the communication hole 421c inside the housing portion 423 after removing the device

main bodies

101, 111 and 121 from the cradle 30. Since it can be brought into contact with the first seal portion 422 or the second seal portion 425, the internal space 45 of the connection port 40 can be easily sealed.

In addition, in the drug-

solution administration devices

100 and 110 according to the present embodiment, the connection port 40 includes a lever portion 424 having one end connected to the housing portion 423 and the other end extending to the outside of the cradle 30, and a communication hole 421c. may be configured to be opened by moving the housing portion 423 relative to the liquid medicine introduction portion 421 in the detachment direction D2 as the lever portion 424 is moved in the detachment direction D2.

According to the medicinal-solution administration device 100 configured in this way, the user can easily connect to the liquid-feeding tube 14 by operating the lever portion 424 when the attachment state between the device main body 101 and the cradle 30 is confirmed. It can be fluidly connected to port 40 .

In addition, in the medical-solution administration device 100 according to the present embodiment, the communication hole 421c moves the housing portion 423 relative to the medical-solution introduction portion 421 in the mounting direction D1 as the lever portion 424 moves in the mounting direction D1. It may be configured such that it is closed by doing so.

According to the drug-solution administration device 100 configured in this way, the user pushes the lever portion 424 when detaching the device main body 101 from the cradle 30 or when detaching the device main body 101 from the device main body 101 and the cradle 30 . When operated, the internal space 45 of the connection port 40 can be easily closed from the external environment.

In addition, in the drug-solution administration device 110 according to this embodiment, the cradle 30 has an opening 31e in the mounting surface portion 31a on which the device main body 111 is mounted, and the connection port 40 has one end connected to the housing portion 423. , the other end of which is positioned on the lower surface of the cradle 30, and has a lever portion 424 provided with an engaging claw 424c provided at a position facing the opening 31e when the apparatus main body 111 is attached to the cradle 30; has an engaging recess 11f provided on the lower surface of the bottom surface portion 11a at a position facing the opening 31e when the device main body 111 is attached to the cradle 30. As shown in FIG. The engaging claws 424c and the engaging recesses 11f are engaged through the openings 31e when the device main body 111 is attached to the cradle 30, and the housing portion 423 prevents the device main body 111 from moving in the detaching direction D2 from the cradle 30. Accordingly, until the engagement between the engaging claw 424c and the engaging recess 11f is released, the movement of the lever portion 424 in the separating direction D2 interlocks with the movement of the lever portion 424 in the separating direction D2 relative to the liquid medicine introduction portion 421. to close the communication hole 421c.

According to the medicinal-solution administration device 110 configured in this way, the user can move the lever portion 424 and the housing portion 423 connected to the lever portion 424 in the detachment direction D2 simply by detaching the device main body 111 from the cradle 30. Since the communication hole 421c is thus closed, the internal space 45 of the connection port 40 can be easily sealed.

Further, in the drug solution administration device 120 according to the present embodiment, the connection port 40 includes a biasing member 421g that biases the housing part 423 in a direction to separate the drug solution introduction part 421. 121 may be configured to move relative to the drug solution introduction portion 421 in the detachment direction D2 by the biasing member 421g to close the communication hole 421c as the urging member 421g moves in the detachment direction D2 from the cradle 30 .

According to the medicinal-solution administration device 120 configured in this way, the user only needs to detach the device main body 121 from the cradle 30, and the urging member 421g moves the housing portion 423 in the detachment direction D2 to open the communication hole 421c. Since it is closed, the internal space 45 of the connection port 40 can be easily sealed.

In addition, in the drug-

solution administration devices

110 and 120 according to the present embodiment, the communication hole 421c is provided on the peripheral surface of the hollow cylindrical protrusion 421d provided at the tip of the drug-solution introduction part 421, and the housing part 423 communicates with The connection port 40 is provided with a first sealing portion 422 that is in close contact with the hole 421c. It may be configured as

In the drug-

solution administration devices

110 and 120 configured in this manner, the communication hole 421c is in close contact with the first seal portion 422, so the internal space 45 of the connection port 40 can be reliably sealed.

In addition, in the drug-

solution administration devices

110 and 120 according to the present embodiment, the device

main bodies

111 and 121 have contact portions 16b that contact the housing portion 423 when the device

main bodies

111 and 121 are attached to the cradle 30. When the device

main bodies

111 and 121 are attached to the cradle 30, the contact portion 16b of the port 40 presses the housing portion 423 in the attachment direction D1, thereby releasing the contact between the first seal portion 422 and the communication hole 421c. may be configured to be fluidly connected to the liquid transfer port 16 .

According to the medical-

solution administration devices

110 and 120 configured in this manner, the user can reliably move the housing portion 423 in the mounting direction D1 simply by mounting the device

main bodies

111 and 121 on the cradle 30.

This application is based on Japanese Patent Application No. 2021-050936 filed on March 25, 2021, the disclosure of which is incorporated by reference in its entirety.

10 first main body,
11 housing (11a bottom surface, 11f engagement recess)
12 reservoir,
14 liquid feed pipe,
16 liquid feeding port (16a liquid feeding hole, 16b contact portion),
20 second main body,
23 liquid feeding driving unit,
30 cradles,
31 holder case (31a placement surface, 31e opening),
40 connection port,
42 first connecting portion (421 chemical solution introduction portion, 421b tip surface of chemical solution introduction portion, 421f communication hole, 421g biasing member, 422 first seal portion, 423 housing portion, 424 lever portion, 423a mounting portion, 423b housing portion inner surface, 424c engaging claw),
43 second connection,
50 cannulas,
100, 110, 120 drug solution administration device,
101, 111, 121 device main body (101a bottom portion),
D1 mounting direction,
D2 Departure direction.

Claims

a cradle attached to the living body and attached with a connection port for holding a cannula to be inserted into the living body;
A reservoir that stores a chemical solution, a liquid-sending driving unit that delivers the chemical solution from the reservoir, a liquid-sending pipe through which the chemical solution sent from the reservoir flows, and a liquid-sending port that communicates with the liquid-sending pipe. a device body comprising
A drug-solution administration device in which the liquid-feeding port and the connection port are detachably fluidly connected,
The connection port includes a chemical solution introducing portion having a communication hole for inflowing the chemical solution sent from the liquid sending tube, and a housing portion mounted with the liquid sending port and movable with respect to the chemical solution introducing portion. ,
By sliding the housing portion relative to the liquid introduction portion in a direction in which the device main body is attached to and detached from the cradle, the communication hole is opened to be fluidly connected to the liquid transfer port. , drug solution administration device.
The communication hole is provided in the chemical introduction portion facing the inner surface of the housing portion,
As the housing portion moves in the attachment/detachment direction, the outer peripheral surface of the liquid medicine introduction portion of the communication hole is sealed by a seal portion accommodated inside the housing portion, thereby allowing the liquid medicine administration device to flow. 2. The drug solution administration device according to claim 1, wherein the channel is opened and closed.
the connection port includes a lever portion having one end connected to the housing portion and the other end extending to the outside of the cradle;
The communication hole is opened when the housing moves relative to the chemical solution introduction part in the direction of separation as the lever moves in the direction of separation of the apparatus main body from the cradle. 3. The drug-solution administration device according to claim 1 or 2.
The communication hole is closed by the housing portion moving in the mounting direction relative to the liquid medicine introduction portion as the lever portion moves in the mounting direction opposite to the disengagement direction. Item 4. The drug-solution administration device according to Item 3.
The cradle has an opening in a mounting surface on which the device main body is mounted,
One end of the connection port is connected to the housing portion, the other end is located on the lower surface of the cradle, and an engaging claw provided at a position facing the opening when the device main body is attached to the cradle. having a lever portion comprising
the apparatus main body has an engaging recess provided on the lower surface of the bottom surface portion at a position facing the opening when the apparatus main body is attached to the cradle,
the engaging claw and the engaging recess are engaged through the opening when the device main body is attached to the cradle;
The housing portion moves the lever portion in the detaching direction until the engagement between the engaging claw and the engaging recess is released as the device body moves in the detaching direction from the cradle. 3. The medical-solution administration device according to claim 1, configured to move relative to said medical-solution introducing portion in said detaching direction in association with said movement to close said communicating hole.
the connection port includes an urging member that urges the housing section in a direction to separate the drug solution introduction section;
The housing portion is moved relative to the liquid medicine introduction portion in the direction of separation by the biasing member as the main body of the apparatus moves in the direction of separation from the cradle, thereby closing the communication hole. 3. The drug-solution administration device according to claim 1, wherein the drug-solution administration device is configured as
The communication hole is provided on the peripheral surface of a hollow cylindrical protrusion provided at the tip of the chemical solution introduction part,
The housing portion includes a first seal portion that is in close contact with the communication hole,
7. The connection port according to any one of claims 1 to 6, wherein when the device main body is removed from the cradle, the communication hole is in close contact with the first seal portion to seal the inside. Chemical liquid administration device.
the device main body includes a contact portion that contacts the housing portion when the device main body is attached to the cradle;
When the device main body is mounted on the cradle, the connection port is configured such that the first seal portion and the communication hole are connected by pushing the housing portion in the mounting direction of the device main body with respect to the cradle by the abutting portion. 8. The drug-solution administration device according to claim 7, wherein the liquid-feeding port is fluidly connected to the liquid-feeding port after being released from close contact with the liquid-feeding port.